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Trypstatin, a new cellular Kunitz-type protease inhibitor purified from rat mast cells, inhibited syncytium formation in 
human immunodeficiency virus type 1 (HIV-l)-infected CCRF-CEM and uninfected Molt-4 clone 8 at a concentration 
of 1 pM. Anti-rat tongue mast cell tryptase antibodies reacted with Molt-4 clone 8 cells, as determined by Western blot 
and by immunofluorescence. In addition, the antibody inhibited syncytium formation. These findings along with homolo- 
gous sequences with trypstatin and a neutralizing epitope of gpl20 of HIV-l suggest that a tryptase-like cellular enzyme(s) 
is involved in HIV-l infection. 
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1. INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-l), 
a causative agent of acquired immunodeficiency 
syndrome (AIDS), infects cells via interactions be- 
tween cellular receptors (CD4 molecules) and the 
external envelope glycoprotein (gp 120) [ 1,2]. The 
mechanism by which HIV-l enters host cells after 
binding has, however, not yet been clarified. 
Previous studies showed that neutralization of en- 
dosomal compartments with lysosomotropic 
agents did not effectively inhibit HIV-l nucleocap- 
sid entry into the cytoplasm, and HIV-l infection 
was observed even if the subunit of the CD4 
molecule, necessary for internalization of the 
molecule, was absent as a result of genetic deletion 
[3,4]. These findings suggest that post-binding 
events of HIV-l on cell surfaces are necessary for 
infection of cells by HIV-l. Experiments using syn- 
thetic peptides, encoding gp120, and a neutralizing 
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monoclonal antibody clarified that the epitope 
consisting of 24 amino acids at positions 308-331 
of gp120 is essential for infection by the HTLV- 
IIIB viral strain [5,6]. Furthermore, the epitope 
portion of gp120 is different from the domain of 
gp120 (amino acid residues 367-439), which plays a 
role in the binding of gp120 to CD4 molecules [7]. 
Successive studies clarified that the neutralizing 
epitope is homologous to the active sites of inter-a- 
trypsin inhibitor and human urinary trypsin in- 
hibitor (UTI), and the synthetic peptide correspon- 
ding to the epitope inhibited trypsin activities. In 
addition, at concentrations ranging from 100 pM 
to 1 mM, UT1 and the synthetic peptide inhibited 
syncytium formation caused by HIV-l-infected 
and uninfected T cell lines. These findings suggest 
that the neutralizing epitope might be accessible to 
an unknown cellular protease upon infection 
(Koito, A., submitted). Recently, a new cellular 
Kunitz-type protease inhibitor, trypstatin, was 
purified from rat peritoneal mast cells and some of 
its amino acid sequences were also homologous 
with the neutralizing epitope [S,9]. Trypstatin in- 
hibits tryptase activities in rat mast cells. In this 
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communication, we have examined the effects of 
trypstatin and antibodies against tryptase on 
HIV-l infection using HIV-l-susceptible T cell 
lines. 
2. MATERIALS AND METHODS 
2.1. Purification of trypstatin and preparations of anti- 
tryptase antibodies 
Trypstatin and tryptase from rat peritoneal mast cells were 
purified by the methods of Kido et al. [8,10]. Tryptase from 
tongue and tryptase from lung were also purified from tongue 
and lung mast cells, respectively (Kido, H. and Katunuma, N., 
in preparation). These enzyme preparations and trypstatin ap- 
peared homogeneous after polyacrylamide gel electrophoresis 
with sodium dodecyl sulfate (SDS-PAGE). Antisera against 
tryptase from different tissues were obtained from rabbits (New 
Zealand Whites). Each purified protease was emulsified with an 
equal volume of Freund’s complete adjuvant and was injected 
into rabbits intracutaneously at doses of lOOpg/rabbit. 3 weeks 
later, the rabbits were given subcutaneous weekly booster injec- 
tions of 50rg of the proteases with complete Freund’s adjuvant 
for 3 weeks, and were bled 10 days after the last injection. Im- 
munoglobulin G (IgG) (1.8 mg/ml) was prepared by the method 
of Arnon and Shapira [1 11. Each antiserum stained granules of 
mast cells in the source tissue. 
2.2. Western blot 
Western blot was carried out as described previously [12]. The 
cell lysates obtained were fractionated by SDS-PAGE on a 12% 
acrylamide gel and were transferred to nitrocellulose. Individual 
nitrocellulose blots were treated with I:200 rabbit antibodies 
against tryptase from various sources and with normal rabbit 
IgG. The second antibody used was biotinylated goat anti-rabbit 
antibody and bound antibodies were visualized by an enzyme 
immunoassay, using horseradish peroxidase-conjugated avidin 
as the indicating enzyme. Cell lines used were Molt-4 clone 8, 
which is highly susceptible and forms giant cells within several 
hours of cultivation with HIV-l-infected CCRF-CEM cells [IJ]. 
Another human T cell leukemia virus type I (HTLV-1)-infected 
cell line, called SKT-lB, was also used. This cell line has ac- 
tivated T cell features, is also susceptible to HIV-l infection and 
dies after exposure to HIV-l without forming syncytia [14]. 
2.3, Cell surface staining 
Surface expression of tryptase was examined using the anti- 
tryptase antibody. Anti-tongue tryptase was chosen for this ex- 
periment, because the antibody reacted most strongly with both 
cell lines (Molt-4 clone 8 and SKT-1B) on Western blots. Nor- 
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Fig.1. Amino acid alignment of the neutralizing epitope of 
gpl20 of HIV-l and trypstatin. The numbers are from [6] and 
[8], respectively. A one-letter amino acid code is used and the 
box indicates homologous regions. 
ma1 peripheral blood mononuclear cells (PBMC) or con- 
canavalin A (Con-A: Calbiochem Behring Corp., La Jolla, CA) 
-activated PBMC (5 /rg/ml for 3 days) were also analysed for 
surface tryptase expression. One million cells from each line 
were incubated with 50 ~1 of 1:lOO diluted rabbit anti-tongue 
tryptase antibody or normal rabbit IgG for 30 min on ice. The 
second antibody used was fluorescein isothiocyanate- 
conjugated goat F(ab’)l anti-rabbit IgG (Tago Inc., Burl- 
ingame, CA). For the analysis of PBMC, stained cells were fur- 
ther reacted with phycoerythrin-conjugated Leu 4 (CD3) 
monoclonal antibody (Beckton and Dickinson Monoclonal 
Center, Mountain View, CA) to identify T cells. Stained cells 
were analysed by a laser flow cytometry (FACStar, Beckton and 
Dickinson Immunocytometry Systems, Mountain View, CA), 
using either single or two color analyses, respectively. Antigen- 
positive cells were expressed as a percentage of total T cells. 
2.4. Effects of trypstatin and anti-tongue tryptase antibody 
on syncytium formation 
HIV-l (LAV-1) [IS] -infected CCRF-CEM cells (2 x 104 cells 
per well) and Molt-4 clone 8 cells (1 x 10s cells per well) were 
washed twice with RPM1 1640 medium (Nissui, Tokyo) and co- 
cultured in %-well microtiter plates (Falcon, Oxnard, CA) in the 
presence or absence of trypstatin or anti-tongue tryptase an- 
tibody. The cells were co-cultured in serum-free medium, 
ASF-104 (Ajinomoto, Tokyo) to avoid non-specific effects of 
protease and protease inhibitors in fetal calf serum, in a 
humid atmosphere with 5% CO1 at 37OC, and the plates were in- 
termittently shaken. After 12 h of culture, syncytia formation 
was examined under an inverted microscope (magnification x 
200). 
Fig.2. Western blot with anti-rat tryptase antibody. Cellular exi 
tracts of Molt-4 clone 8 (A) and SKT-1B (B) were used as an- 
tigens. Antibodies used were anti-tongue (lane 1), anti-lung 
(lane 2), anti-peritoneal (lane 3) mast cell tryptase and control 
rabbit IgG (lane 4). 
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Table 1 3. RESULTS 
Cell surface staining with anti-tongue tryptase antibody. 
Relative proportion of antigen-positive cells 
Cells %I 
Molt-4 clone 8 96.6 
Molt-4 87.0 
SKT-1B 7.9 
Resting Ta 0.2 
Activated T 7.8 
a CD3-positive cells in non-activated PBMC 
3.1. Homologies of trypstatin and neutralizing 
epitope of HIV 
Fifty percent homology was found between 
amino acid residues 316 and 328, a part of the 
neutralizing epitope of HIV-l [5,6] and residues 
7-19 of trypstatin (fig.1). Interestingly, a highly 
conserved P-turn (GPGR) in the homologous 
regions is believed to be critical for antibody 
binding and type-specific virus neutralization [161. 
Fig.3. Effects of trypstatin and anti-tongue tryptase antibody on syncytium formation. (a) Molt-4 clone 8 atone (negative control); (b) 
LAV-l-infected CCRF-CEM and Molt-4 clone 8 (positive control); (c) trypstatin (1 PM); (d) trypstatin (300 nM); (e) rabbit anti-tongue 
tryptase antibody (6OO~g/ml); (f) rabbit anti-tongue tryptase antibody (2OO,&ml). 
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In addition, the reactive site of trypstatin may be pg/ml also inhibited syncytium formation, but 
the R [14] and A [15] judging from the sequence significant inhibition was not observed at the lower 
homology [8]. concentration of 200 pg/ml (fig.3). 
3.2. Western blot 
The Western blot was carried out using cellular 
extracts of Molt-4 clone 8 and SKT-1B [14] cells as 
antigens. The antibodies used included anti- 
tongue, anti-lung, anti-peritoneal mast cell tryptase 
antibodies and rabbit IgG as a control (fig.2). Con- 
trol rabbit IgG bound non-specifically to proteins 
of 100 and 65 kDa in SKT-1B cells, and to a 100 
kDa protein from Molt-4 clone 8 cells. However, 
anti-tongue and anti-peritoneal mast cell tryptase 
antibody recognized a 39 kDa protein in Molt-4 
clone 8 cells, with the anti-tongue tryptase an- 
tibody staining this protein more clearly. However, 
anti-lung tryptase antibody did not react with 
Molt-4 clone 8 cells and SKT-1B cells. Anti-tongue 
tryptase antibody gave three bands, corresponding 
to 39, 36 and 25 kDa in SKT-1B cells. It is likely 
that the 39 kDa protein is important, and the 36 
and 25 kDa proteins found in SKT-1B may be 
breakdown products of the 39 kDa protein. 
4. DISCUSSION 
Amino acid residues 308-331 of gp120 were 
found to be critical for neutralization of HIV-l in- 
fection. The roles of this epitope in HIV-l infection 
have not been clarified, but it is different from the 
site at which gp120 binds to CD4 molecules [5-71. 
Our previous studies suggest that this portion may 
be nicked by cellular trypsin-type protease or in- 
teracts with these protease after binding of 
HIV-l to the CD4 molecule, due to its homology to 
the reactive sites of the inter-cr-trypsin inhibitor. In 
addition, human UTI, which is thought to be a pro- 
teolytic product of inter-cu-trypsin inhibitor, in- 
hibits syncytium formation at relatively high con- 
centrations (1 mM-100pM) (Koito, A; submitted). 
3.3. Antigen density of tryptase on cells 
Cellular tryptase antigen density was measured 
using the anti-tongue tryptase antibody (table 1). 
Around 90010 of Molt-4 and Molt-4 clone 8 cells 
were anti-tongue tryptase antibody-positive. 
Before activation, less than 1% of PBMCs were 
double positive, that is CD3 +, anti-tongue 
tryptase+ , but increased to 7.8% after activation 
with Con-A. These findings suggest that T cells 
may express tryptase-like enzymes on cell surfaces 
after mitogen stimulation. Almost 8% of SKT-1B 
cells reacted with anti-tongue tryptase antibody, 
similar to activated T cells. 
In this report, we demonstrate marked inhibitory 
effects of HIV-l infection by a new cellular pro- 
tease inhibitor, trypstatin, derived from rat mast 
cells. The assumed reactive site of trypstatin also 
has high homology to the conserved core portion of 
the neutralizing epitope of gp120, as shown in 
fig. 1. Also, trypstatin inhibits mast cell tryptase 
(Ki = 3.6 x lo-” M), blood coagulation factor Xa 
(Ki= 1.2 x 1O-1o M) and trypsin (Ki= 1.4 x lo-’ 
M) [8,9]. Trypstatin inhibited syncytium formation 
of co-cultured HIV-l-infected CCRF-CEM and 
Molt-4 clone 8 cells at a concentration as low as 1 
PM. The concentration needed to inhibit syncytium 
formation in these cells by trypstatin is 
lOO-lOOO-fold less than that required by UTI. 
These findings show that the effect of trypstatin is 
more specific than the serum and urinary inhibitors 
tested. 
3.4. Effects of trypstatin and anti-tongue tryptase 
antibody on syncytium formation 
The effects of trypstatin and anti-tongue tryp- 
tase antibody on syncytium formation caused by 
LAV-1 -infected CCRF-CEM cells and Molt-4 
clone 8 cells were examined under an inverted 
microscope. The formation of syncytia was in- 
hibited completely by trypstatin at a concentration 
of 1 PM and the inhibition was also observed at a 
lower concentration of trypstatin (300 nM). Anti- 
tongue tryptase antibody at a concentration of 600 
In addition, we found that anti-tongue tryptase 
antibody also inhibited the syncytium formation 
and recognized protein in the extracts of Molt-4 
clone 8 and SKT-1B cells as demonstrated by 
Western blot. Immunofluorescent staining of these 
cells localized the antigen to the cell surface. In ad- 
dition, mitogenic activation of PBMC induces ex- 
pression of the antigen on T cells. The molecular 
mass of the immunoreactive antigen in both Molt-4 
clone 8 and SKT-1B cells on SDS-PAGE was 39 
kDa, which is larger than those of tryptase mole- 
cule from rat tongue and peritoneal mast cells, and 
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than that of rat lung tryptase molecule, which are 
35 and 30 kDa, respectively. From these results, we 
speculate that Kunitz-type protease inhibitors, such 
as trypstatin and UTI, inhibit trypsin-type pro- 
tease(s) on the surface of T cells, which play an 
essential role in HIV-l infection. It has already 
been reported that cellular trypsin-type protease is 
involved in the maturation of HIV-l gp160 to 
gp120 [ 171. It is possible that trypstatin may inhibit 
this process. Alternatively, our findings strongly 
suggest that protease on the T cell surface, which is 
similar to rat tryptase, plays a role in successful 
HIV-l infection of T cells by cleaving neutralizing 
epitope. The nature of the antigens recognized by 
anti-tongue tryptase antibody is at present unclear, 
and their characterization is now in progress. 
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